Ace Vision Group closed a Series A preferred stock round totaling $13.3 million to continue development of its VisioLite ophthalmic laser for the treatment of age-related vision dysfunction, according to a press release.
Robert Picerne of Picerne Group LLC led the funding round.
“This funding round validates Ace Vision Group’s path forward to explore the potential of laser microporation technologies, a new frontier in eye therapy,” AnnMarie Hipsley, DPT, PhD, founder and CEO of Ace Vision Group, said in the release. “Our focus is to provide a first-in-class novel
Uncategorized